[go: up one dir, main page]

PL2582366T3 - Kombinacja farmaceutyczna do leczenia bólu - Google Patents

Kombinacja farmaceutyczna do leczenia bólu

Info

Publication number
PL2582366T3
PL2582366T3 PL11730199T PL11730199T PL2582366T3 PL 2582366 T3 PL2582366 T3 PL 2582366T3 PL 11730199 T PL11730199 T PL 11730199T PL 11730199 T PL11730199 T PL 11730199T PL 2582366 T3 PL2582366 T3 PL 2582366T3
Authority
PL
Poland
Prior art keywords
pain
treatment
pharmaceutical combination
pharmaceutical
combination
Prior art date
Application number
PL11730199T
Other languages
English (en)
Inventor
Klaus Schiene
Petra Bloms-Funke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2582366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL2582366T3 publication Critical patent/PL2582366T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11730199T 2010-06-15 2011-06-14 Kombinacja farmaceutyczna do leczenia bólu PL2582366T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15
PCT/EP2011/002905 WO2011157391A1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain
EP11730199.4A EP2582366B1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain

Publications (1)

Publication Number Publication Date
PL2582366T3 true PL2582366T3 (pl) 2016-04-29

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11730199T PL2582366T3 (pl) 2010-06-15 2011-06-14 Kombinacja farmaceutyczna do leczenia bólu

Country Status (29)

Country Link
US (3) US8846765B2 (pl)
EP (2) EP2992877A1 (pl)
JP (3) JP6133772B2 (pl)
KR (1) KR101831616B1 (pl)
CN (1) CN103108631B (pl)
AR (1) AR081931A1 (pl)
AU (2) AU2011267474B2 (pl)
BR (1) BR112012031836A2 (pl)
CA (1) CA2796774C (pl)
CL (1) CL2012002551A1 (pl)
CO (1) CO6602157A2 (pl)
CY (1) CY1117118T1 (pl)
DK (1) DK2582366T3 (pl)
EC (2) ECSP12012217A (pl)
ES (1) ES2560676T3 (pl)
HK (1) HK1215787A1 (pl)
HR (1) HRP20151327T1 (pl)
HU (1) HUE026619T2 (pl)
IL (1) IL221926A (pl)
MX (1) MX2012014482A (pl)
NZ (1) NZ602625A (pl)
PE (2) PE20130243A1 (pl)
PL (1) PL2582366T3 (pl)
PT (1) PT2582366E (pl)
RS (1) RS54439B1 (pl)
RU (2) RU2589692C2 (pl)
SI (1) SI2582366T1 (pl)
WO (1) WO2011157391A1 (pl)
ZA (1) ZA201208646B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN104519878A (zh) * 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
HK1217170A1 (zh) 2013-01-22 2016-12-30 维斯塔津治疗公司 L-4-氯犬尿氨酸的剂型和治疗用途
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
RU2721948C2 (ru) * 2014-05-06 2020-05-25 Нортвестерн Юниверсити Комбинации соединений, модулирующих nmda-рецептор
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
JP7532718B2 (ja) 2018-04-12 2024-08-14 アナベックス ライフ サイエンス コーポレイション 物質のａ２－７３結晶多形組成物およびそれらの使用方法
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
EP1102589B1 (en) * 1998-07-16 2006-11-02 Memorial Sloan-Kettering Institute For Cancer Research Topical compositions comprising an opioid analgesic and an nmda antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
US20060240128A1 (en) * 2002-09-09 2006-10-26 Schlagheck Thomas G Combined immediate release and extended release analgesic composition
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
DE602007011913D1 (de) 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
RU2465263C2 (ru) 2006-04-28 2012-10-27 Грюненталь Гмбх Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
AU2007256352A1 (en) 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
WO2009067703A2 (en) * 2007-11-23 2009-05-28 Nectid, Inc. Tapentadol compositions
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
LT2735338T (lt) * 2008-09-05 2019-04-10 Grünenthal GmbH 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
MX2013003354A (es) 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
PT2826467T (pt) 2010-12-22 2017-10-25 Purdue Pharma Lp Formas envolvidas de dosamento de libertação controlada resistentes à adulteração
MX348831B (es) 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
CN110101702A (zh) 2012-04-17 2019-08-09 普渡制药公司 用于治疗阿片样物质所致不良药效学响应的系统和方法

Also Published As

Publication number Publication date
EP2582366A1 (en) 2013-04-24
ZA201208646B (en) 2013-09-25
JP2013528629A (ja) 2013-07-11
JP6423036B2 (ja) 2018-11-14
KR20130111945A (ko) 2013-10-11
KR101831616B1 (ko) 2018-04-04
RU2675261C2 (ru) 2018-12-18
CA2796774C (en) 2020-06-02
JP2017141277A (ja) 2017-08-17
CO6602157A2 (es) 2013-01-18
US20170333369A1 (en) 2017-11-23
ECSP12012217A (es) 2012-11-30
RU2013101515A (ru) 2014-07-20
US10813890B2 (en) 2020-10-27
CN103108631A (zh) 2013-05-15
RU2589692C2 (ru) 2016-07-10
RU2016119041A (ru) 2017-11-20
HK1215787A1 (en) 2016-09-15
JP6133772B2 (ja) 2017-05-24
DK2582366T3 (en) 2015-12-07
US20110306674A1 (en) 2011-12-15
AU2016219643B2 (en) 2018-04-12
PE20130243A1 (es) 2013-03-22
EP2582366B1 (en) 2015-10-28
HUE026619T2 (en) 2016-06-28
AU2011267474B2 (en) 2016-05-26
RS54439B1 (sr) 2016-06-30
ES2560676T3 (es) 2016-02-22
CA2796774A1 (en) 2011-12-22
HRP20151327T1 (hr) 2016-01-01
AR081931A1 (es) 2012-10-31
IL221926A (en) 2015-08-31
CL2012002551A1 (es) 2012-11-09
HK1184370A1 (zh) 2014-01-24
US8846765B2 (en) 2014-09-30
NZ602625A (en) 2014-03-28
JP6197007B2 (ja) 2017-09-13
US20140309311A1 (en) 2014-10-16
PE20160531A1 (es) 2016-06-05
BR112012031836A2 (pt) 2016-11-08
CY1117118T1 (el) 2017-04-05
CN103108631B (zh) 2015-08-26
ECSP19047259A (es) 2019-07-31
PT2582366E (pt) 2016-01-26
WO2011157391A1 (en) 2011-12-22
MX2012014482A (es) 2013-02-21
EP2992877A1 (en) 2016-03-09
JP2015232015A (ja) 2015-12-24
AU2011267474A1 (en) 2013-01-10
SI2582366T1 (sl) 2016-02-29
AU2016219643A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
CY2021031I2 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
IL222132B (en) Use of cannabidivarin for the preparation of medicaments for treating epilepsy or epileptic seizures
EP2474280A4 (en) SURGICAL TREATMENT DEVICE
FI20105569L (fi) Kehonsisäinen hoitolaite
DK3162386T3 (da) Implanterbare medicinske indretninger
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
CO6930321A2 (es) Curación de tejidos
EP2465446A4 (en) TREATMENT INSTRUMENT FOR ENDOSCOPE
BR112012033478A2 (pt) dispositivo médico
PT2709604T (pt) Canabidivarina para utilização no tratamento de dor neuropática
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
DK2652652T3 (da) Medikmentadministration
PT2632300T (pt) Almofada cervical para o tratamento de doenças da coluna cervical
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
IL234606B (en) Novel methods and composition for treatment of disease
EP2415408A4 (en) Treatment device
PL2900230T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
ZA201301458B (en) Therapeutic agent for pain